Sanofi (SNY) Shares are Down -1.22%

Sanofi (SNY) : During the past 4 weeks, traders have been relatively bearish on Sanofi (SNY), hence the stock is down -6.6% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.19% relative to the S&P 500. The 4-week change in the price of the stock is -6.24% and the stock has fallen -1.22% in the past 1 week.

Sanofi has dropped 0.68% during the last 3-month period . Year-to-Date the stock performance stands at -3.07%. The stock has recorded a 20-day Moving Average of 3.27% and the 50-Day Moving Average is 2.6%.


Sanofi (NYSE:SNY): The stock opened at $39.28 on Friday but the bulls could not build on the opening and the stock topped out at $39.73 for the day. The stock traded down to $39.16 during the day, due to lack of any buying support eventually closed down at $39.67 with a loss of -0.23% for the day. The stock had closed at $39.76 on the previous day. The total traded volume was 1,112,246 shares.

Also, Equity analysts at the Brokerage firm Barclays upgrades its rating on Sanofi (NYSE:SNY). The rating major has initiated the coverage with overweight rating on the shares. Earlier, the shares were rated a Equal-weight by the brokerage firm. The rating by the firm was issued on May 12, 2016.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.